JP2012502904A5 - - Google Patents

Download PDF

Info

Publication number
JP2012502904A5
JP2012502904A5 JP2011526872A JP2011526872A JP2012502904A5 JP 2012502904 A5 JP2012502904 A5 JP 2012502904A5 JP 2011526872 A JP2011526872 A JP 2011526872A JP 2011526872 A JP2011526872 A JP 2011526872A JP 2012502904 A5 JP2012502904 A5 JP 2012502904A5
Authority
JP
Japan
Prior art keywords
compound
poly
opioid
less
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011526872A
Other languages
English (en)
Japanese (ja)
Other versions
JP5827123B2 (ja
JP2012502904A (ja
Filing date
Publication date
Priority claimed from US12/558,395 external-priority patent/US8173666B2/en
Application filed filed Critical
Priority claimed from PCT/US2009/005174 external-priority patent/WO2010033195A1/en
Publication of JP2012502904A publication Critical patent/JP2012502904A/ja
Publication of JP2012502904A5 publication Critical patent/JP2012502904A5/ja
Application granted granted Critical
Publication of JP5827123B2 publication Critical patent/JP5827123B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011526872A 2008-09-16 2009-09-16 乱用の可能性が低いpeg化オピオイド Expired - Fee Related JP5827123B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US19224708P 2008-09-16 2008-09-16
US61/192,247 2008-09-16
US12/558,395 2009-09-11
US12/558,395 US8173666B2 (en) 2007-03-12 2009-09-11 Oligomer-opioid agonist conjugates
PCT/US2009/005174 WO2010033195A1 (en) 2008-09-16 2009-09-16 Pegylated opioids with low potential for abuse

Publications (3)

Publication Number Publication Date
JP2012502904A JP2012502904A (ja) 2012-02-02
JP2012502904A5 true JP2012502904A5 (enExample) 2012-11-08
JP5827123B2 JP5827123B2 (ja) 2015-12-02

Family

ID=41611345

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011526872A Expired - Fee Related JP5827123B2 (ja) 2008-09-16 2009-09-16 乱用の可能性が低いpeg化オピオイド

Country Status (10)

Country Link
US (2) US20110237614A1 (enExample)
EP (2) EP3342427A1 (enExample)
JP (1) JP5827123B2 (enExample)
KR (1) KR101660996B1 (enExample)
CN (1) CN102159249A (enExample)
AU (1) AU2009292631A1 (enExample)
CA (1) CA2734333A1 (enExample)
IL (1) IL211762A (enExample)
MX (1) MX347741B (enExample)
WO (1) WO2010033195A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
CN1407884B (zh) 1999-10-29 2012-06-20 欧罗赛铁克股份有限公司 控释氢可酮制剂
WO2002036099A1 (en) 2000-10-30 2002-05-10 Euro-Celtique S.A. Controlled release hydrocodone formulations
US20080069891A1 (en) 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
US10512644B2 (en) 2007-03-12 2019-12-24 Inheris Pharmaceuticals, Inc. Oligomer-opioid agonist conjugates
US8173666B2 (en) 2007-03-12 2012-05-08 Nektar Therapeutics Oligomer-opioid agonist conjugates
EP2456469A1 (en) * 2009-07-21 2012-05-30 Nektar Therapeutics Oligomer-opioid agonist conjugates
US20130023553A1 (en) * 2010-01-12 2013-01-24 Nektar Therapeutics Pegylated opioids with low potential for abuse and side effects
BR112012028788A2 (pt) 2010-05-10 2016-07-19 Euro Celtique Sa fabricação de grânulos sem ativos
MX2012012991A (es) 2010-05-11 2012-11-30 Cima Labs Inc Formas de dosificacion oral de liberacion prolongada resistentes al alcohol y que contienen metoprolol.
AU2012336030B2 (en) * 2011-11-07 2017-09-14 Nektar Therapeutics Compositions, dosage forms, and coadministration of an opioid agonist compound and an analgesic compound
US10525054B2 (en) 2011-11-07 2020-01-07 Inheris Biopharma, Inc. Compositions, dosage forms, and co-administration of an opioid agonist compound and an analgesic compound
EP2895457B1 (en) 2012-09-17 2020-05-20 Nektar Therapeutics Oligomer-containing benzamide-based compounds
HUE038161T2 (hu) 2012-10-30 2018-09-28 Nektar Therapeutics Alfa-6-mPEG6-O-hidroxikodon szilárd só formája, mint opioid agonisták, és ezek alkalmazásai
CA2881144A1 (en) * 2012-11-09 2014-05-09 Purdue Pharma Pharmaceutical compositions comprising hydromorphone and naloxone
EP3013812B1 (en) * 2013-06-28 2019-10-16 Nektar Therapeutics Kappa opioid agonists and uses thereof
JP6539274B2 (ja) 2013-08-12 2019-07-03 ファーマシューティカル マニュファクチュアリング リサーチ サービシズ,インコーポレーテッド 押出成形された即放性乱用抑止性丸剤
US20150118300A1 (en) 2013-10-31 2015-04-30 Cima Labs Inc. Immediate Release Abuse-Deterrent Granulated Dosage Forms
CA2929909C (en) 2013-11-13 2018-08-21 Euro-Celtique S.A. Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
EP3169315B1 (en) 2014-07-17 2020-06-24 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
US20160106737A1 (en) 2014-10-20 2016-04-21 Pharmaceutical Manufacturing Research Services, Inc. Extended Release Abuse Deterrent Liquid Fill Dosage Form
US11066366B2 (en) 2015-09-03 2021-07-20 Allegheny-Singer Research Institute Hydrophilic fentanyl derivatives
CN107019803B (zh) * 2016-01-29 2020-09-15 北京键凯科技股份有限公司 具有低成瘾作用的聚乙二醇化阿片样物质
CN107033154B (zh) * 2016-02-02 2020-02-04 上海瀚迈生物医药科技有限公司 阿片受体拮抗剂缀合物及其应用
CN108210933B (zh) * 2016-12-22 2021-05-04 北京键凯科技股份有限公司 一种地佐辛与聚乙二醇的结合物
AU2018302253B2 (en) * 2017-07-20 2023-06-01 Suzhou Runxindatai Pharmaceutics Ltd Co. Abuse-resistant long-acting release opioid prodrugs
CA3095299A1 (en) 2018-03-29 2019-10-03 Nof Corporation Method for purifying trityl group-containing monodispersed polyethylene glycol
US11324707B2 (en) 2019-05-07 2022-05-10 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
US20220062200A1 (en) 2019-05-07 2022-03-03 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
CN115181109B (zh) * 2021-04-02 2024-06-04 南京正大天晴制药有限公司 吗啡喃衍生物的晶体及其制备方法

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2654756A (en) * 1949-10-20 1953-10-06 Mallinckrodt Chemical Works Process of preparing codeinone, dihydrocodeinone, and dihydromorphinone
US2628962A (en) * 1949-10-20 1953-02-17 Mallinckrodt Chemical Works Method for preparing dihydrocodeinone, dihydromorphinone, and codeinone
US2715626A (en) * 1950-07-05 1955-08-16 Merck & Co Inc Process of preparing dihydrocodeinone
US2649454A (en) 1951-08-20 1953-08-18 Univ California Method for preparing dihydromorphinone, dihydrocodeinone, and dihydropseudocodeinone
US2806033A (en) * 1955-08-03 1957-09-10 Lewenstein Morphine derivative
US3254088A (en) * 1961-03-14 1966-05-31 Lewenstein Morphine derivative
JPS60149589A (ja) * 1984-01-14 1985-08-07 Daiichi Rajio Isotope Kenkyusho:Kk クラウン化コデイノン類
US5843900A (en) * 1991-04-01 1998-12-01 Cortech, Inc. Bradykinin antagonists
DE4132159A1 (de) * 1991-09-27 1993-04-01 Boehringer Ingelheim Kg 14-hydroxy-n-(2-methoxyethyl)-7,8-dihydromorphin und -norisomorphin, verfahren zu deren herstellung und deren verwendung als arzneimittel
US5428159A (en) * 1994-04-08 1995-06-27 Ciba-Geigy Corporation Method of manufacture of (-)-galanthamine in high yield and purity substantially free of epigalanthamine
US5672662A (en) * 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
US6004577A (en) * 1997-08-12 1999-12-21 Murdock; Thomas O. Enhanced electrotransport of therapeutic agents having polybasic anionic counter ions
US6703381B1 (en) * 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
US6395300B1 (en) * 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US7919119B2 (en) * 1999-05-27 2011-04-05 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
EP1221975B1 (en) * 1999-10-04 2006-12-06 Nektar Therapeutics Al, Corporation Polymer stabilized neuropeptides
US20050233459A1 (en) * 2003-11-26 2005-10-20 Melker Richard J Marker detection method and apparatus to monitor drug compliance
US7049326B2 (en) * 2000-05-12 2006-05-23 The University Of Toledo Method and compositions for temporarily incapacitating subjects
DE10025946A1 (de) * 2000-05-26 2001-11-29 Gruenenthal Gmbh Wirkstoffkombination
US20070258894A1 (en) * 2000-11-08 2007-11-08 Melker Richard J System and Method for Real-Time Diagnosis, Treatment, and Therapeutic Drug Monitoring
US20020106331A1 (en) * 2000-12-08 2002-08-08 Joan Rosell Use of electrolytes (ions in solution) to suppress charging of inhalation aerosols
JP4850346B2 (ja) * 2001-03-15 2012-01-11 救急薬品工業株式会社 粘膜貼付剤
US6858580B2 (en) * 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6835802B2 (en) 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
CN1514729B (zh) * 2001-06-05 2012-09-05 控制释放系统公司 缓释的止痛化合物
US7338939B2 (en) * 2003-09-30 2008-03-04 New River Pharmaceuticals Inc. Abuse-resistant hydrocodone compounds
PT2939696E (pt) * 2001-10-18 2016-06-17 Nektar Therapeutics Conjugados poliméricos de antagonistas de opióides
ATE358275T1 (de) * 2001-11-16 2007-04-15 Randox Lab Ltd Verfahren und kit zum nachweis, oder zum quantifizieren von, metaboliten von fentanyl und metaboliten von fentanyl analoga
FR2832311B1 (fr) * 2001-11-21 2004-04-16 Besins Int Belgique Poudre filmogene, compositions la comprenant, leurs procedes de preparation et leurs utilisations
TW200500067A (en) * 2003-01-21 2005-01-01 Control Delivery Sys Inc Salts of codrugs and uses related thereto
EP1782834A3 (en) * 2003-03-13 2007-08-01 Controlled Chemicals, Inc. Oxycodone conjugates with lower abuse potential and extended duration of action
ATE454169T1 (de) * 2003-03-13 2010-01-15 Controlled Chemicals Inc Oxycodon- konjugate mit niedrigerem missbrauch- potential und ausgedehnter tätigkeitsdauer
US20060009478A1 (en) * 2003-10-15 2006-01-12 Nadav Friedmann Methods for the treatment of back pain
US20060182692A1 (en) * 2003-12-16 2006-08-17 Fishburn C S Chemically modified small molecules
US7786133B2 (en) * 2003-12-16 2010-08-31 Nektar Therapeutics Chemically modified small molecules
JP2007532645A (ja) * 2004-04-13 2007-11-15 アルザ コーポレイション フェンタニルに基づく薬剤の経皮送達システム用の器具および方法
AU2005283326B2 (en) * 2004-09-13 2011-07-21 Ono Pharmaceutical Co., Ltd. Nitrogenous heterocyclic derivative and medicine containing the same as an active ingredient
WO2006126529A1 (ja) * 2005-05-25 2006-11-30 Shionogi & Co., Ltd. 6,7-不飽和-7-カルバモイル置換モルヒナン誘導体
KR20080080087A (ko) * 2005-09-30 2008-09-02 티티아이 엘뷰 가부시키가이샤 신규 약학 담체를 이용한 경피 약물 전달시스템, 장치 및방법
MX2008013594A (es) * 2006-04-21 2009-01-16 Nektar Therapeutics Al Corp Reduccion estereoselectiva de una morfinona.
US8217005B2 (en) * 2006-05-26 2012-07-10 Signature Therapeutics, Inc. Controlled release of phenolic opioids
US20080066739A1 (en) * 2006-09-20 2008-03-20 Lemahieu Edward Methods and systems of delivering medication via inhalation
WO2008036980A1 (en) * 2006-09-22 2008-03-27 Alltranz Inc. Transdermally deliverable buprenorphine prodrugs and abuse-resistant compositions thereof
CA2667259A1 (en) * 2006-11-07 2008-05-15 Nektar Therapeutics Al, Corporation Dosage forms and co-administration of an opioid agonist and an opioid antagonist
EP2129683A4 (en) * 2007-02-26 2011-01-05 Ironwood Pharmaceuticals Inc METHODS AND COMPOSITIONS FOR TREATMENT OF HEART FAILURE AND OTHER DISORDERS
US8173666B2 (en) * 2007-03-12 2012-05-08 Nektar Therapeutics Oligomer-opioid agonist conjugates
SI2134371T1 (sl) * 2007-03-12 2015-04-30 Nektar Therapeutics Konjugati agonista oligomer-opioid
JP5693967B2 (ja) * 2008-01-25 2015-04-01 ウェルズ ファーゴ バンク ナショナル アソシエイション オリゴマー−ジアリールピペラジンコンジュゲート
US20090246265A1 (en) * 2008-03-26 2009-10-01 Alltranz Inc. Abuse deterrent transdermal formulations of opiate agonists and agonist-antagonists
WO2009151590A2 (en) * 2008-06-09 2009-12-17 Nektar Therapeutics Methods of treating cyp2d6 alternative metabolizers
US20100016365A1 (en) * 2008-07-17 2010-01-21 Auspex Pharmaceuticals, Inc. Substituted 4-amino-piperidines
US20110165248A1 (en) * 2008-09-18 2011-07-07 Meridith Lee Machonis Pharmaceutical dosage forms comprising poly(e-caprolactone)
US20130023553A1 (en) * 2010-01-12 2013-01-24 Nektar Therapeutics Pegylated opioids with low potential for abuse and side effects

Similar Documents

Publication Publication Date Title
JP2012502904A5 (enExample)
Venditto et al. Cancer therapies utilizing the camptothecins: a review of the in vivo literature
US10265409B2 (en) Macromolecules
US8461171B2 (en) Hybrid opioid compounds and compositions
ES2654819T3 (es) Conjugados poliméricos de antagonistas de opioides
JP5877403B2 (ja) オリゴマー−オピオイドアゴニスト複合体
WO2008076333A8 (en) Polymer-drug conjugates with tether groups for controlled drug delivery
KR102811484B1 (ko) 치료 덴드리머
JP2011530597A (ja) マルチアームポリマーアルカノエートコンジュゲート
JP6076317B2 (ja) 対象において持続的治療薬濃度を実現するための組成物及び方法
US20210100910A1 (en) Macromolecules
JP6223995B2 (ja) カンプトテシン類と抗癌効果増強剤の結合した高分子化合物及びその用途
JP2008542399A5 (enExample)
Hegde et al. An update on design and pharmacology of dendritic poly (l-lysine)
JP2004502789A5 (enExample)
CN112996533B (zh) 基于聚合物的大分子前药
US12071517B2 (en) Therapeutic dendrimer
WO2010083154A3 (en) Heterofunctional segment-poly(ethylene glycol) polymers as delivery vehicles
WO2025101904A1 (en) Norepinephrine transporter-targeted prodrugs for cancer therapy